Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ: TECH) launched the SARS-CoV-2 Multi-Antigen Serology Module for its Simple Western automated systems. This new assay detects human IgG antibodies against five SARS-CoV-2 antigens within three hours, processing up to 23 samples simultaneously. The module promises to enhance COVID-19 research by providing a detailed view of immune responses, offering quicker, reproducible results compared to traditional methods. Bio-Techne emphasizes its commitment to supporting vaccine developers and researchers with this advanced technology.

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on November 5, 2020, at 8:00 a.m. CST to discuss its first quarter 2021 financial results. Investors can access the live call via phone or online. A replay will be available after the call until December 5, 2020. Bio-Techne, a leader in developing purified proteins and diagnostic products, reported approximately $739 million in net sales for fiscal 2020 and employs around 2,300 staff worldwide.

Bio-Techne Corporation (NASDAQ:TECH) has opened a new office in Toronto, Canada, housing approximately 40 employees. This facility aims to support the Canadian life sciences industry and will service academic and biopharma clients with Bio-Techne's life science tools and diagnostic reagents. The Toronto office will also manufacture and distribute cartridges for the Protein Simple branded iCE and Maurice systems, enhancing the company’s production capacity. Designed for energy efficiency, it meets ISO 9001 standards to ensure high-quality operations.

Bio-Techne Corporation (NASDAQ: TECH) announced the grand opening of a 61,000 square foot GMP manufacturing facility in St. Paul, MN, investing $50 million. This facility aims to support large-scale production of GMP-grade materials essential for cell and gene therapies, particularly E. coli-derived recombinant proteins. With a growing demand driven by immuno-oncology and stem cell therapies, Bio-Techne is positioned to enhance its manufacturing capabilities and meet global market needs. Production is expected to begin in early 2021 after quality validation procedures.

Bio-Techne Corporation (NASDAQ:TECH) announced a publication in BMC Urology regarding the ExoDx Prostate test (EPI). Conducted by Dr. James McKiernan and colleagues, the study found that EPI achieved a 92% negative predictive value for ruling out high-grade prostate cancer in men with prior negative biopsies, potentially avoiding 27% of unnecessary repeat biopsies. Prostate cancer remains a significant health concern, with over 3.6 million men living with it in the U.S. This study underscores the test's clinical benefits, elevating patient and physician confidence in biopsy decisions.

Bio-Techne Corporation (NASDAQ: TECH) announced the launch of its RNA-Protein Co-Detection Assays, enhancing the RNAscope™ technology. This innovation allows simultaneous examination of gene expression and secreted proteins in intact cells and tissues, addressing the challenges of traditional ISH and IHC methods. The assays utilize patented RNAscope and BaseScope™ technologies for improved specificity and sensitivity. Bio-Techne aims to combine its extensive antibody portfolio with RNAscope technology, facilitating advanced research in infectious diseases and cancer biology.

Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its B-MoGen Biotechnologies portfolio to R&D Systems on September 21, 2020. This change includes the retirement of the B-MoGen website, with all products and services now accessible through R&D Systems' site. President Dave Eansor highlighted that this consolidation aims to enhance service offerings for cell and gene therapy customers, providing value-added services alongside high-quality products. More details on the TcBuster gene transfer system can be found on their new site.

Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. have expanded their non-exclusive partnership focusing on exosome technology. The agreement allows QIAGEN to use Bio-Techne's exosome technology for developing companion in vitro diagnostic products. This partnership will promote the technology among biopharma partners for an initial 24 months, potentially extendable. Furthermore, both companies are extending their exclusive collaboration for product development through Exosome Diagnostics until 2028, enhancing marketing efforts around exosome technologies.